Description
Dabrafenib
Each LuciDabra Capsule contains: 88.88mg Dabrafenib mesylate equivalent to Dabrafenib … 75mg
INDICATION
LuciDabra is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation. LuciDabra is indicated, in combination with trametinib, for: • The treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations. • The adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations and involvement of lymph node(s), following complete resection. • The treatment of patients with metastatic non -small cell lung cancer (NSCLC) with BRAF V600E mutation. • The treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options. Limitations of Use: LuciDabra is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF NSCLC, or wild-type BRAF ATC.
DOSAGE AND USE
The recommended dosage of LuciDabra is 150 mg orally twice daily. Take LuciDabra at least 1 hour before or at least 2 hours after a meal. The capsule should be swallowed whole & not chewed or crushed.
STORAGE
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of the reach of Children. Do not administered LuciDabra in Pregnancy and Lactation patient treatment
Reviews
There are no reviews yet.